Home World News Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in... World News Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC By Ogkologos - September 7, 2026 130 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-671 study after 5 years of follow-up Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Laser-Based Device Detects and Kills Melanoma Cells in the Blood, Study... July 25, 2019 April is Occupational Therapy (OT) Month- What is OT and how... April 8, 2021 Alcohol linked to more than 740,000 new cancer cases globally in... July 14, 2021 New on NCI Websites for July 2019 July 2, 2019 Load more HOT NEWS First-Line Treatment with Atezolizumab Associated with Improved OS in Patients with... Poorer Survival in Obese Colorectal Cancer Patients Possibly Linked to Lower... EMA Recommends Extension of Therapeutic Indications for Atezolizumab Mobile Care Center Brings Breast Cancer Treatment to Amish and Mennonite...
